Prasad Krishnamurthy

Dr. Prasad Krishnamurthy is currently associated with East Ocyon Bio, India as Chief Scientific Officer. He also consults for other biotech startup organizations involved in biosimilars and gene therapy product development. He has obtained his PhD from Centre for Cellular and Molecular Biology, Hyderabad, India and worked as a post-doctoral scientist at Columbia University Medical Center, NY, US with Prof. Eric Greene. He has close to two decades of experience in Indian biotech industry and has been associated with some of the major biotech companies in India such as Dr. Reddy’s, Biocon, Syngene, Intas biopharma and Aurobindo pharma. He has deep understanding of drug discovery, biosimilars, gene and cell therapy product development processes.

Dr. Prasad held various positions of increasing responsibilities within R&D of various biotech organizations and contributed to the development of several biosimilar products such as adalimumab, denosumab, pertuzumab, GCSF and peg-GCSF to name a few. He initiated AAV based gene therapy product and CAR-T cell therapy product development at Intas. At East Ocyon Bio, he oversees the development of NK cell and gamma delta T cell based allogeneic cell therapy products in the pipeline.